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Summary
Background Complement is a key component of the innate immune system, and variation in genes that regulate its 
activation is associated with renal and other disease. We aimed to establish the genetic basis for a familial disorder of 
complement regulation associated with persistent microscopic haematuria, recurrent macroscopic haematuria, 
glomerulonephritis, and progressive renal failure.
Methods We sought patients from the West London Renal and Transplant Centre (London, UK) with unusual renal 
disease and aﬀ ected family members as a method of identiﬁ cation of new genetic causes of kidney disease. Two 
families of Cypriot origin were identiﬁ ed in which renal disease was consistent with autosomal dominant transmission 
and renal biopsy of at least one individual showed C3 glomerulonephritis. A mutation was identiﬁ ed via a genome-
wide linkage study and candidate gene analysis. A PCR-based diagnostic test was then developed and used to screen 
for the mutation in population-based samples and in individuals and families with renal disease.
Findings Occurrence of familial renal disease cosegregated with the same mutation in the complement factor H-related 
protein 5 gene (CFHR5). In a cohort of 84 Cypriots with unexplained renal disease, four had mutation in CFHR5. 
Overall, we identiﬁ ed 26 individuals with the mutation and evidence of renal disease from 11 ostensibly unrelated 
kindreds, including the original two families. A mutant CFHR5 protein present in patient serum had reduced aﬃ  nity 
for surface-bound complement. We term this renal disease CFHR5 nephropathy.
Interpretation CFHR5 nephropathy accounts for a substantial burden of renal disease in patients of Cypriot origin 
and can be diagnosed with a speciﬁ c molecular test. The high risk of progressive renal disease in carriers of the 
CFHR5 mutation implies that isolated microscopic haematuria or recurrent macroscopic haematuria should not be 
regarded as a benign ﬁ nding in individuals of Cypriot descent.
Funding UK Medical Research Council and Wellcome Trust.
Introduction
Kidney disease is an important cause of morbidity and 
mortality worldwide. In many cases, renal injury results 
from damage caused by the immune system, either 
in response to microbial infection or because of 
inappropriate activation of defence mechanisms. The 
mechanisms that protect the kidney from immunological 
attack in healthy individuals—and that fail in disease—
are not well understood.
The complement system is a key component of host 
defence, and variation in the genes that regulate 
complement activation is associated with disease, 
including age-related macular degeneration,1,2 atypical 
haemolytic uraemic syndrome,2–4 and glomerulo-
nephritis.2,5–7 The kidney is especially susceptible to the 
eﬀ ects of complement activation, and glomerulo nephritis 
(a leading cause of kidney failure worldwide) is generally 
characterised by presence of complement within the 
glomerulus. Typically, complement is accompanied by 
immunoglobulins, which activate it via the classical 
pathway. However, complement deposition can occur 
without immunoglobulin via the complement alternative 
pathway. This deposition occurs in dense-deposit disease, 
which is caused by genetic or acquired defects in 
complement regulation.5
Isolated glomerular C3 deposition and inﬂ ammation 
can also arise in the absence of dense-deposit disease. 
This heterogeneous entity has been termed 
C3 glomerulonephritis and is often associated with the 
histological appearance of membranoproliferative 
glomerulonephritis.7 Our aim was to investigate an 
inherited renal disease, which we show is endemic in 
Cyprus and is characterised by microscopic and 
synpharyngitic macroscopic haematuria, renal failure, 
and C3 glomerulonephritis.
Methods
Patients
To detect high penetrance genes leading to kidney 
disease, we identiﬁ ed multiply aﬀ ected kindreds of 
patients from the West London Renal and Transplant 
Centre (London, UK), prioritising those with an unusual 
renal condition, syndromic features, or early onset of 
disease. Family 1 in this report lived in London, UK, and 
reported ancestry from the Troodos mountains of Cyprus. 
The index patient from family 2 was referred to us from 
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Cyprus with C3 glomerulonephritis and, because he also 
came from the Troodos region and C3 glomerulonephritis 
is very rare, we postulated that he might have the same 
genetic condition as individuals from family 1. Individuals 
from both families were tested for evidence of renal 
disease and underwent genetic analysis, leading to 
identiﬁ cation of a shared mutation.
To establish the frequency of this genetic mutation, 
we searched for carriers in two cohorts. We examined 
DNA for 102 unrelated individuals in the UK 1958 birth 
cohort8 and 1015 control participants in the MASTOS 
study in Cyprus.9 
We sought additional individuals in Cyprus by screening 
for the presence of the mutation in a cohort of 84 Cypriot 
patients with advanced or end-stage chronic renal disease, 
either of unknown cause or because of presumed or 
incompletely characterised glomerulo nephritis. A further 
two families from Cyprus (family 3 and family 4) were 
tested for the mutation because they had familial renal 
disease in which other conditions had been sought 
and excluded.10 In these families, microscopic and 
synpharyngitic macroscopic haematuria segregated as an 
autosomal dominant trait and direct exon sequencing 
excluded recognised mutations of COL4A3 and COL4A4.10 
We sought additional individuals in London, UK, by 
reviewing case records from the West London Renal and 
Transplant Centre and the Royal Free Renal Unit for 
potentially aﬀ ected individuals, looking for histological 
features consistent with CFHR5 nephropathy. This 
search identiﬁ ed four further individuals who were 
shown to have the mutation. One patient had a brother 
with microscopic haematuria, who was also found to 
have the mutation (family 5). 
Finally, we analysed DNA from 36 individuals with a 
renal biopsy diagnosis of C3GN (deﬁ ned as 
glomerular C3 deposition in the absence of 
immunoglobulin staining for IgG, IgM, and IgA, and 
without intramembranous glomerular basement 
membrane dense deposits) and no recognised family 
history; 34 individuals were from France (including 19 
reported previously7) and two were from the UK. 
Additional single nucleotide polymorph isms (SNPs) 
were genotyped in three members of ﬁ ve families 
(CytoSNP 12 panel, Illumina, CA, USA) to deﬁ ne the 
maximum possible extent of the shared haplotype 
spanning the locus. Estimation of the probable number 
of generations since the common aﬀ ected ancestor of 
the families was done as previously described.11 Formal 
retinal examination was done by an ophthalmologist 
from Moorﬁ elds Eye Hospital, London, UK for two 
individuals (IV-5 and V-4) from family 1.
The study was approved by the local research ethics 
committees and participants provided written consent.
Genetic analysis 
Individuals from families 1 and 2 were tested for 
evidence of renal disease, and DNA was extracted from 
blood or saliva (Oragene, DNA Genotek, Kanata, ON, 
Canada). Genotypes and haplotypes of 6008 SNPs 
(Linkage IV panel, Illumina, CA, USA) from these two 
families were analysed with EasyLINKAGE,12 
PEDCHECK,13 GENEHUNTER version 2.1,14 and 
HAPLOPAINTER.15 Bidirectional sequencing of the 
exons of candidate genes was done after PCR 
ampliﬁ cation (primers available from the authors 
on request).
CFHR5 internal duplication was assessed by multiplex 
ligation-dependent probe ampliﬁ cation (MLPA), which 
was done with unampliﬁ ed genomic DNA with the 
P236 A1 ARMD mix 1 (MRC-Holland, Amsterdam, 
Netherlands). Southern blotting was done with genomic 
DNA digested with EcoR1 (New England Biolabs, MA, 
USA). Membranes were probed with a ³²P-labelled 
371 base pair sequence containing exon 2 of CFHR5. PCR 
ampliﬁ cation of the CFHR5 duplication insertion point 
used the primers 5 -´TGGAAGCCTGTGGTATAAATGA-3´ 
and 5 -´TCCGGCACATCCTTCTCTAT-3 .´ Screening PCR 
to amplify both CFHR5 alleles in a single reaction 
used the primers 5 -´GATTCCATTTGTCAAATATTG-3 ,´ 
5 -´TCTTCTCCAAAACTATCTAATGTCAA-3 ,´ and 5 -´TTT
GAATGCTGTTTTAGCTCG-3 .´
For the multiplex 
ligation-dependent probe 
ampliﬁ cation procedure see 
http://www.mrc-holland.com
Figure 1: Pedigrees of two ostensibly unrelated families from the Troodos mountain region, Cyprus, showing 
haplotypes at region of maximum linkage on chromosome 1
Green boxes are haplotypes (HapMap coordinates 192344247 to 201027281).
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Serum CFHR5 detection and functional analysis
We used western blotting to detect CFHR5 in serum 
and recombinant CFHR5 in supernatants using a rabbit 
polyclonal anti-human-CFHR5 antibody16 (a gift from 
J McRae, Immunology Research Centre, Melbourne, 
Australia). Functional analysis of CFHR5 protein 
binding to heparin and lysed chicken erythrocytes was 
done as previously described.16,17 Brieﬂ y, patient serum 
was incubated with chicken erythrocytes, which 
spontaneously activated the alternative pathway 
resulting in cell lysis and binding of CFHR5 to the 
disrupted membranes. The relative amounts of unbound 
CFHR5 protein (supernatant) and bound CFHR5 
protein (erythrocyte membrane pellet) were established 
by western blotting. 
Role of the funding source
The funding bodies of the study had no role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. PHM and MCP had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Renal disease segregated as an autosomal dominant trait 
in family 1 and family 2 (ﬁ gure 1). Disease was 
characterised by persistent microscopic haematuria and 
episodes of synpharyngitic macroscopic haematuria 
(within 1–2 days of an upper respiratory tract infection). 
C3 glomerulonephritis was identiﬁ ed in renal biopsy 
specimens in aﬀ ected male and female patients. 
Glomerular inﬂ ammation was variable, but subendothelial 
and mesangial deposits that were reactive with antibody 
to C3, but not to C1q, C4, or immunoglobulins, were 
always present in these patients. Subepithelial deposits 
were occasionally noted. Figure 2 shows a representative 
biopsy sample. 
In family 1, a genome-wide SNP-based analysis that 
used an autosomal dominant model and scored all 
patients with haematuria as aﬀ ected established linkage 
to an 18 cM (centimorgan) region of chromosome 
1q31–32 (logarithm of the odds [LOD] score 2·22). With 
the addition of family 2, the combined LOD score was 
3·40 (ﬁ gure 3). A haplotype of 17 SNPs spanning 8·74 cM 
within the linked region was shared by all aﬀ ected 
members of both families, which is consistent with 
inheritance of an allele at this locus from a common 
ancestor (ﬁ gure 1). This haplotype (HapMap coordinates 
192344247 to 201027281) included complement factor H 
(CFH) and CFH-related (CFHR) 1–5 genes. Sequencing 
of CFH and two of the CFH-related genes (CFHR1 and 
CFHR5) in patients V-4 and IV-5 (both family 1) did not 
reveal any mutations.
MLPA analysis detected a heterozygous deletion of 
CFHR1 and CFHR3 in three members of family 2 
(ﬁ gure 4), which did not segregate with renal disease and 
is a polymorphism present in 14·2% of healthy controls.18 
MLPA analysis also showed heterozygosity for a previously 
unreported duplication of exons 2 and 3 of CFHR5 in 
aﬀ ected individuals from family 1 (IV-5 and V-4) and 
family 2 (II-1 and III-2), but not in the unaﬀ ected 
individual in family 2 (II-2) (ﬁ gure 4). The CFHR5 internal 
duplication was conﬁ rmed, and its size established, by 
Southern hybridisation of genomic DNA with CFHR5 
exon 2. The boundary of the duplication was identiﬁ ed by 
resequencing a PCR product (ﬁ gure 5). Figure 5 shows an 
additional 6·3 kbp fragment on Southern blot analysis in 
aﬀ ected individuals from family 1 (IV-5 and V-4) and 
family 2 (II-1 and III-2). This band was not present in two 
unrelated control individuals or in an unaﬀ ected 
individual from family 2 (II-2), in whom only the expected 
7·9 kbp band was seen. With a reverse primer positioned 
in CFHR5 exon 2 and a forward primer in intron 3, there 
was no ampliﬁ cation from wild-type DNA (as expected). 
The duplication of exons 2 and 3 in DNA with the 
mutation led to a product of 4·8 kbp with these primers. 
Sequencing of this product conﬁ rmed the position and 
size of the duplication. A diagnostic PCR test was then 
designed with three primers which gave a 298 bp product 
from the wild-type allele and an additional 222 bp product 
from the allele with the CFHR5 internal duplication. The 
222 bp product was seen in aﬀ ected but not unaﬀ ected 
members of families 1 and 2 (ﬁ gure 6).
With this diagnostic PCR, we did not detect a CFHR5 
internal duplication in 102 randomly selected partici-
pants from the UK 1958 birth cohort.8 The CFHR5 
internal duplication was only detected in one individual 
of 1015 control participants in the MASTOS study (for 
Figure 2: Renal biopsy sample of patient V-4 from family 1
(A) Periodic acid-Schiﬀ  stain of glomerulus demonstrating mesangial hypercellularity (arrow). (B) Immunoperoxidase 
stain for C3 showing granular staining on the capillary wall. (C and D) Electron micrographs showing prominent 
mesangial electron-dense deposits (black arrow), subendothelial deposits (arrowheads), and occasional subepithelial 
deposits (white arrow).
A B
C D
200 μm 200 μm
2 μm2 μm
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whom no clinical or personal details were available).9 
The CFHR5 internal duplication is therefore a rare allele 
in the Cypriot population.
We then screened a cohort of 84 patients in Cyprus with 
advanced or end-stage renal failure. This screening 
identiﬁ ed one female and three male patients with the 
mutation, none of whom reported ancestry in the Troodos 
mountains. Families 3 and 4 were identiﬁ ed by testing 
Cypriot families with unexplained haematuria, and the 
CFHR5 duplication was identiﬁ ed in all seven individuals 
aﬀ ected with microscopic or synpharyngitic macroscopic 
haematuria, but not in ﬁ ve unaﬀ ected relatives. A renal 
biopsy had been taken from one individual from these 
families and showed C3 glomerulonephritis. Neither of 
these families could trace their ancestry to the Troodos 
mountains region. The review of case records from two 
renal units in London followed by DNA testing identiﬁ ed 
three men and one woman of Cypriot descent with 
CFHR5 nephropathy. In one of these cases a brother with 
microscopic haematuria was also tested and found to 
have the CFHR5 mutation (family 5). Although not 
ostensibly related to family 1 or family 2, paternal ancestry 
was from the same valley in the Troodos Mountains.
The table summarises available clinical data for all the 
individuals we showed had the CFHR5 mutation or who 
were obligate carriers. In all aﬀ ected men, there was 
progressive renal impairment with end-stage renal 
disease between the ages of 40 and 69 years. Renal 
impairment was less common in aﬀ ected women than in 
aﬀ ected men (p=0·0016; table).
These ﬁ ndings suggest that the newly identiﬁ ed CFHR5 
duplication accounts for a substantial proportion of renal 
disease in Cyprus and is not conﬁ ned to the Troodos 
mountain region. Further genotyping of SNPs showed a 
haplotype extending from 1·4 cM upstream to 4·7 cM 
downstream of the mutation that cosegregated with the 
CFHR5 internal duplication in the ﬁ ve families tested, 
which is consistent with inheritance of the mutation by all 
aﬀ ected individuals from an original founder. By contrast, 
none of the 36 individuals with biopsies showing 
C3 glomerulonephritis from the UK and France had the 
CFHR5 mutation.
CFHR5 is a 65 kDa plasma protein consisting of nine 
short consensus repeat (SCR) domains (repeating units 
that are characteristic of CFH and CFHR proteins).16 
Duplication of exon 2 (encoding SCR1) and exon 3 
(encoding SCR2), predicted a novel CFHR5 protein with 
duplicated SCR domains 1 and 2 (ﬁ gure 7). Western 
Figure 3: Genome-wide single-nucleotide polymorphism-based analysis
LOD=logarithm of the odds.
Figure 4: Multiplex ligation-dependent probe ampliﬁ cation analysis of CFH and CFHR genes using genomic DNA from ﬁ ve individuals from families 1 and 2
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blotting of serum samples from aﬀ ected individuals 
detected the normal CFHR5¹²³-⁹ (superscript numbers 
denote SCRs) protein, and a slow migrating protein that 
was consistent with the predicted molecular weight of 
CFHR5¹²¹²³-⁹ (ﬁ gure 7).
Although the initial aminoacid sequence of the wild-
type SCR1 is Glu-Gly-Thr-Leu-Cys-Asp (with the ﬁ rst 
glutamic acid encoded by exon 1), the duplicated SCR1 is 
encoded only by exon 2 and therefore is predicted not to 
have this glutamic acid. Splicing of exon 3 upstream of 
the exon 2 sequence results in a change in the initial 
codon of the duplicated SCR1 so that the second 
aminoacid in the sequence is arginine rather than 
glycine. Hence, the initial aminoacid sequence of the 
duplicated SCR1 is predicted to be Arg-Thr-Leu-Cys-Asp. 
The rest of the duplicated SCR1 aminoacid sequence 
and entire duplicated SCR2 aminoacid sequence is 
identical to wild-type CFHR5.
The physiological role of CFHR5 is not known; the 
plasma concentration is estimated to be 3–6 μg/mL,19 
which is approximately 1% of that of the well characterised 
complement regulator CFH.20 CFHR5 has been shown to 
co-localise with complement deposits in diseased human 
kidneys21 and binds to surface-bound activated C3 (termed 
C3b).16 We showed that mutant CFHR5¹²¹²³-⁹ protein 
bound less eﬀ ectively than did wild-type protein to two 
sources of surface-bound complement; complement-
lysed erythrocyte membranes (ﬁ gure 8) and glomerular-
bound mouse complement (webappendix p 1).
Previous in-vitro investigations have reported that 
CFHR5 shares some of the complement regulatory 
activities of CFH; CFHR5 can be a cofactor for the 
proteolytic inactivation of complement C3b by the plasma 
enzyme complement factor I, although its activity is weak 
by comparison with that of CFH.19 We conﬁ rmed that 
both the wild-type CFHR5 and mutant CFHR5¹²¹²³-⁹ 
proteins have complement factor I cofactor activity; in 
both cases the activity is substantially weaker than that 
reported for CFH. The mutant CFHR5¹²¹²³-⁹ protein did 
not have reduced activity compared with wild-type in this 
assay; perhaps surprisingly, complement factor I cofactor 
activity was increased (webappendix p 2).
Discussion
We provide evidence for an inherited renal disease, 
endemic in Cyprus, that is characterised by microscopic 
and synpharyngitic macroscopic haematuria, renal 
failure, and C3 glomerulonephritis, and show that 
aﬀ ected individuals have an internal duplication within 
the gene for complement factor H-related protein 5 
(CFHR5). We term this disease CFHR5 nephropathy.
Isolated microscopic haematuria is a common 
presentation that in the absence of urinary tract 
abnormalities, proteinuria, or renal impairment is usually 
believed to be benign, and with present guidelines is not 
investigated by renal biopsy.22,23 However, this study shows 
that isolated microscopic haematuria can be the 
presenting feature of progressive renal disease, with 
implications for patients and their families. Furthermore, 
analysis of data suggests that familial isolated microscopic 
haematuria attributable to heterozygous mutations in 
COL4A3 and COL4A4 is also associated with progressive 
Figure 5: Southern blot of EcoR1-digested genomic DNA from two unrelated controls (C1 and C2) and ﬁ ve 
individuals from families 1 and 2, probed with exon 2 of CFHR5
Arrows show orientation of PCR primers. Numbered black rectangles are CFHR5 exons. Double-headed arrows are 
EcoR1 restriction fragments. Red triangle shows the duplicated region. 
Figure 6: Diagnostic PCR test for CFHR5¹²¹²³-⁹
Arrowhead shows one 298 bp product in the wild-type allele and arrows shows 
the 222 bp product in the allele associated with CFHR5 internal duplication.
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chronic kidney disease.10 Taken together, these ﬁ ndings 
underscore the importance of any history of renal disease 
in the family and the value of renal biopsy and genetic 
investigations in this setting.
CFHR5 nephropathy has several noteworthy clinical 
features. First, the risk of progressive renal impairment is 
more common in men than in women. Second, since 
Berger’s original description,24 repeated episodes of syn-
phar yngitic haematuria have been regarded as almost 
diag nostic of IgA nephropathy; CFHR5 nephropathy 
should now be thought of as a diﬀ erential diagnosis. 
Third, although retinopathy is a well recognised feature of 
dense-deposit disease, with aﬀ ected individuals developing 
ocular drusen at a young age, clinically signiﬁ cant visual 
impair ment was not a feature of CFHR5 nephropathy. 
This ﬁ nding is consistent with a study25 that reported no 
association between CFHR5 polymorphisms and risk of 
age-related macular degeneration. However, because 
formal ophthalmological assessment was only done for 
two aﬀ ected individuals in this study, we cannot exclude 
the presence of subclinical ocular disease in CFHR5 
nephropathy.
An important pathological consideration was that most of 
the individuals who were biopsied initially had a histological 
diagnosis of membranoproliferative glomerulonephritis 
type 1. Review led to recognition that these abnormalities 
were C3 glomerulonephritis, which is an entity described 
in a French report7 of 19 patients that did not identify 
families with more than one aﬀ ected individual. In that 
series,7 men were not more severely aﬀ ected than were 
women, synpharyngitic macroscopic haematuria was not 
reported, and microscopic haematuria was absent in seven 
of 19 (37%) patients at diagnosis. By contrast, CFHR5 
nephropathy is an inherited disease, characterised by 
synpharyngitic macroscopic haematuria (noted in seven 
[58%] of the aﬀ ected individuals tested; see table) and 
microscopic haematuria (all aﬀ ected individuals tested). 
Thus, CFHR5 nephropathy constitutes a distinct clinical 
entity that is associated with the histological category 
C3 glomerulonephritis. Abnormalities in other 
complement genes were identiﬁ ed in a subset of the 
patients in the French report,7 suggesting that diﬀ erent 
mechanisms of complement dysregulation can lead to 
much the same histological appearances.
The CFHR5¹²¹²³-⁹ mutation is a copy number variation 
(ie, a duplication or deletion of a segment of DNA), which 
is not detectable with standard exon-based sequencing. 
Copy number variations arise through non-allelic 
recombination events that are more common in regions 
of complex genomic architecture such as the CFH and 
CFHR1–5 gene cluster.
The extent of the shared haplotype suggests that aﬀ ected 
members of the families inherited the mutation from a 
common ancestor about 16 generations ago,11 and our 
identiﬁ cation of additional cases and aﬀ ected families in 
the Cypriot population implies the existence of a 
substantial number of individuals with CFHR5¹²¹²³-⁹. The 
high penetrance of haematuria (all 22 mutation carriers 
tested; see table), the wide geographical distribution of 
ancestry within Cyprus, and the presence of aﬀ ected 
individuals in the UK suggests that this disease will 
account for a substantial proportion of renal disease 
aﬀ ecting inhabitants of the island and their descendants 
worldwide. Population-based studies need to be done to 
quantify this proportion; we examined only a small cohort 
of Cypriots with advanced or end-stage renal disease, 
either of unknown cause or attributed to presumed or 
incompletely characterised glomerulonephritis. In the 
US renal data system, about 25% of patients with 
advanced renal disease would ﬁ t into this category.
Although CFHR5 nephropathy seems to be a common 
cause of renal disease in the Cypriot population, we did not 
detect this speciﬁ c CFHR5 mutation in 36 cases of sporadic 
C3 glomerulonephritis from France and the UK. Whether 
this geographical disparity is the eﬀ ect of ascertainment 
bias, positive selection for the allele within Cyprus (perhaps 
because of the presence of an endemic infectious disease), 
or genetic drift within the island’s population is not known. 
So far, mutations in other complement regulatory genes 
and the presence of C3 nephritic factor have been reported 
in a few cases of C3 glomerulonephritis;7 other genetic 
abnormalities of CFHR5 might exist.
The mutation we identiﬁ ed in CFHR5 provides a robust 
genetic marker for a novel hereditary nephritis, and 
screening for the mutation is a reliable clinical test. 
Male Female Total
Individuals with CFHR5 mutation 14 12 26
With microscopic haematuria 11/11 11/11 22/22
Obligate carriers with impaired renal function 3/3 0/0 3/3
Conﬁ rmed aﬀ ecteds and obligate carriers with impaired renal function* 13/16† 2/12 15/28
Aﬀ ecteds with synpharyngitic macroscopic haematuria 5/8 2/4 7/12
Biopsy ﬁ ndings in aﬀ ected individuals
Mesangial matrix expansion 6/6 2/3 8/9
Increased glomerular cellularity 6/6 2/3 8/9
Segmental capillary wall thickening 6/6 2/3 8/9
Glomerular staining for C3 6/6 3/3 9/9
Glomerular staining for C1q, IgA, IgG, or IgM 0/6 0/3 0/9
Subendothelial electron-dense deposits 6/6 3/3 9/9
Mesangial electron-dense deposits 6/6 3/3 9/9
Scanty subepithelial electron-dense deposits 4/6 3/3 7/9
CFHR5¹²¹²³¯⁹ detected in serum 7/7 4/4 11/11
Normal serum C3, C4, CFH, and CFI 9/9 5/5 14/14
Negative for C3NeF 2/2 2/2 4/4
Normal retinal appearance‡ 1/1 1/1 2/2
Self-reported visual impairment 0/8 0/7 0/15
Additional ungenotyped ﬁ rst-degree relatives with impaired renal function 5 0 5
Data are number/number of conﬁ rmed aﬀ ecteds and obligate carriers of CFHR5 duplication for whom data were available. 
CFHR5=complement factor H-related protein 5. CFH=complement factor H. CFI=complement factor I. C3NeF=C3 nephritic 
factor. *p=0·0016 men versus women, Fisher’s exact test. †One patient’s DNA and urine was analysed, but no data on renal 
function were available. ‡From fundoscopic examination by ophthalmologist. 
Table: Clinical and pathological ﬁ ndings in CFHR5 nephropathy
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However, our understanding of how the mutation causes 
the disease is incomplete and we do not exclude the 
possibility that another mutation within the 6·1 cM-
shared haplotype could exist. We propose that CFHR5 is 
important in complement processing within the kidney, 
and that the CFHR5¹²¹²³-⁹ mutation impairs the ability of 
CFHR5 to achieve this. Our model is consistent with the 
previous ﬁ nding21 that wild-type CFHR5 co-localises with 
complement within the kidney in renal disease.
Our in-vitro functional studies show that the mutant 
CFHR5¹²¹²³-⁹ protein binds to surface-bound complement 
(on erythrocytes and mouse glomeruli) substantially less 
well than does wild-type CFHR5. Western blot analysis of 
serum from aﬀ ected individuals showed greater intensity 
for mutant CFHR5¹²¹²³-⁹ protein than for wild-type CFHR5 
(ﬁ gure 7); an in-vivo ﬁ nding that would be consistent with 
a defect in recruitment of the mutant protein from the 
circulation to interact with surface-bound complement. 
However, CFHR5¹²¹²³-⁹ is not a straightforward loss of 
functional allele, because it produces a circulating protein 
that shows enhanced complement factor I cofactor activity 
in vitro compared with wild-type CFHR5.
In laboratory models of C3 dysregulation, excessive 
production of inactivated C3b (iC3b) by complement 
factor I is important for the initiation of renal injury;5 
complement factor I cofactor activity of CFHR5¹²¹²³-⁹ 
could lead to an increase in iC3b in the glomerulus. More 
studies will be necessary to elucidate fully the biological 
role of CFHR5 and the pathophysiology of C3 glomerulo-
nephritis in CFHR5 nephropathy. The central role of 
abnormal complement deposition in this disease suggests 
that inhibition of the terminal complement pathway (for 
instance with the humanised anticomplement C5 mono-
clonal antibody eculizumab, which is eﬀ ective for 
treatment of paroxysmal nocturnal haemoglobinuria26) 
might be of therapeutic beneﬁ t in CFHR5 nephropathy 
and clinical studies are needed to address this issue. 
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